REG-4basebio Plc: 4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client's vaccine program

4BasebioAnnouncement

10/04/2024 07:15

  10 April 2024


4basebio PLC

("4basebio" or the "Company")

4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma
client’s vaccine program


Cambridge, UK, 10 April 2024 - 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products and a non-viral, thermostable nucleic
acid delivery platform, today announces the supply of its HQ synthetic DNA to
a Tier 1 Pharma Company. Following successful completion of an opDNA™
evaluation study, our client has now progressed to HQ opDNA™ for late
preclinical studies for an mRNA vaccine program. Supply of GMP grade material
for clinical trials is anticipated in Q3.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

Dr Heikki Lanckriet, CEO at the Company, commented: "This is a major
achievement for our company and is significant both in terms of product
quantity and value. It’s a clear recognition of the strengths of our
synthetic DNA products, our product quality, and our manufacturing
capabilities.

“There is strong interest in our synthetic DNA products, and we are now
supporting a growing number of projects into the clinic. We expect client
acquisition and revenue generation to continue accelerating as our expanding
client base progress their clinical programs.”

For further enquiries, please contact:

 4basebio PLC Heikki Lanckriet                                                          +44 (0)12 2396 7943  
 Nominated Adviser Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson               +44 (0)20 7213 0880  
 Broker   Cavendish Capital Markets Limited Geoff Nash / Charlie Beeson / Nigel Birks   +44 (0)20 7220 0500  
 Lionsgate Communications (Media Enquiries) Jonathan Charles                            +44 (0)77 91892509   

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients. The company is offering GMP compliant DNA starting
materials suitable for use in AAV viral vector production as well as mRNA
vaccine and therapeutics production.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved